NextCure (NASDAQ: NXTC)
NextCure Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
NextCure Company Info
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
News & Analysis
NextCure Delays 2 Clinical Trials Due to Coronavirus
The company cited patient safety concerns and the current strains on hospitals as the reasons for the postponements.
What Does the Future Hold for Nextcure?
Nextcure's solid footing should sustain it despite Eli Lilly's decision to walk away from an R&D pact.
These Were the 10 Best IPOs of 2019
Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.
Is NextCure a Buy?
The recent volatility hasn't been ideal, but it has certainly put the newly public company on the radar of investors.
What Happened in the Stock Market Today
Walgreens rose on a report of a buyout offer while NextCure gave up some of last week's huge gains.
Here's Why NextCure Crashed Today
Highly anticipated clinical trial results didn't continue a promising trend from a smaller number of patients.
Here's Why NextCure Stock Blew Through the Roof Tuesday
Good news from an extremely small number of patients led to Tuesday's enormous bump.
Are There Good Investments Among 2019's Biotech IPOs?
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.